Akeso Biomedical
Mr. Roth is an experienced hedge fund manager and serves as Chief Investment Officer at Severn River Capital Management, LLC, which he founded in 2004. Previously, he was at Sagamore Hill Capital Management, Veritas Capital Management, and HBK Capital Management. Mr. Roth started his career at Goldman Sachs on the convertible-bond-arbitrage desk. He completed an MBA at the Harvard Business School and a BS in chemistry at the US Naval Academy.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Akeso Biomedical
Akeso Biomedical is an early stage company focused on developing new solutions for the treatment of bacterial infections, microbial biofilms, and chronic wounds. The Company is developing products to treat these conditions using a new class of compounds, known as Fe3C, that have broad-spectrum activity against a wide range of bacteria, and a silk biomaterial technology exclusively licensed from Tufts University.